TNX-2300, a Live Virus Vaccine Based on a Bovine Parainfluenza Virus Vector, in Development to Protect Against COVID-19
Co-Expression of the CD40-Ligand Will be Tested to Direct Immune Response
https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-extension-sponsored-110000742.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.